Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response

International Journal of Neuropsychopharmacology

Volumn 7, Issue 4, 2004, Pages 501-506

  Lemonde, Sylvie ^a   Du, Lisheng ^b   Bakish, David ^b   Hrdina, Pavel ^b   Albert, Paul R ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

Flibanserin; Mutation; Pharmacogenetics; Transcription

Indexed keywords

ANTIDEPRESSANT AGENT; FLIBANSERIN; FLUOXETINE; NEFAZODONE; NEUROKININ 1 RECEPTOR ANTAGONIST; NKP 608A; PINDOLOL; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ALLELES; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZIMIDAZOLES; COHORT STUDIES; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PINDOLOL; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, SEROTONIN, 5-HT1A; TRIAZOLES;

EID: 10644242682     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004699     Document Type: Article

References (25)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
2. Arias B, Arranz MJ, Gasto C, Catalan R, Pintor L, Gutierrez B, Kerwin RW, Fananas L (2002). Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT(1A) receptor gene as putative risk factors in major depression. Molecular Psychiatry 7, 930-932.
3. Arias B, Arranz MJ, Gasto C, Catalan R, Pintor L, Gutierrez B, Kerwin RW, Fananas L (2003). Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT(1A) receptor gene as putative risk factors in major depression. Molecular Psychiatry 8, 246.
4. Bakish D, Hooper CL, Thornton MD, Wiens A, Miller CA, Thibaudeau CA (1997). Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. International Clinical Psychopharmacology 12, 91-97.
5. Blier P, Ward NM (2003). Is there a role for 5-HT(1A) agonists in the treatment of depression? Biological Psychiatry 53, 193-203.
6. Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD (2000). Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. American Journal of Medical Genetics 96, 56-60.
7. Fava M, Kendler KS (2000). Major depressive disorder. Neuron 28, 335-341.
8. Gobbi G, Murphy DL, Lesch K, Blier P (2001). Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. Journal of Pharmacology and Experimental Therapeutics 296, 987-995.
9. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, Endicott J, Froom J, Goldstein M, Gorman JM, Marek RG, Maurer TA, Meyer R, Phillips K, Ross J, Schwenk TL, Sharfstein SS, Thase ME, Wyatt RJ (1997). The National Depressive and Manic-Depressive Association consensus Statement on the undertreatment of depression. Journal of the American Medical Association 277, 333-340.
10. Hjorth S (1996). (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxy-tryptamine. European Journal of Pharmacology 303, 183-186.
11. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR (2003). Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. Journal of Neuroscience 23, 8788-8799.
12. Lerer B, Macciardi F (2002). Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. International Journal of Neuropsychopharmacology 5, 255-275.
13. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, Eckelman W, Herscovitch P, Charney DS, Drevets WC (2004). Reduced serotonin type 1A receptor binding in panic disorder. Journal of Neuroscience 24, 589-591.
14. Neumeister A, Konstantinidis A, Stastny J, Schwarz MJ, Vitouch O, Willeit M, Praschak-Rieder N, Zach J, de Zwaan M, Bondy B, Ackenheil M, Kasper S (2002). Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Archives of General Psychiatry 59, 613-620.
15. Pineyro G, Blier P (1999). Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacological Reviews 51, 533-591.
16. Rothe C, Gutknecht L, Freitag C, Tauber R, Mossner R, Franke P, Fritze J, Wagner G, Peikert G, Wenda B, Sand P, Jacob C, Rietschel M, Nothen MM, Garritsen H, Fimmers R, Deckert J, Lesch KP (2004). Association of a functional -1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. International Journal of Neuropsychopharmacology 7, 189-192.
17. Rueter LE, Blier P (1999). Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain. British Journal of Pharmacology 126, 627-638.
18. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809.
19. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychiatry 3, 508-511.
20. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G (1998). Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. Journal of Neuroscience 18, 7394-7401.
21. Strobel A, Gutknecht L, Rothe C, Reif A, Mossner R, Zeng Y, Brocke B, Lesch KP (2003). Allelic variation in 5-HT(1A) receptor expression is associated with anxiety- and depression-related personality traits. Journal of Neural Transmission 110, 1445-1453.
22. Williams JB (2001). Standardizing the Hamilton Depression Rating Scale: past, present and future. European Archives of Psychiatry and Clinical Neuroscience 251, 116-12.
23. Wu S, Comings DE (1999). A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatric Genetics 9, 105-106.
24. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Molecular Psychiatry 7, 1115-1119.
25. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E (2001). Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological Psychiatry 50, 323-330.